179 related articles for article (PubMed ID: 35241721)
1. Radiotherapy alters expression of molecular targets in prostate cancer in a fractionation- and time-dependent manner.
Eke I; Aryankalayil MJ; Bylicky MA; Makinde AY; Liotta L; Calvert V; Petricoin EF; Graves EE; Coleman CN
Sci Rep; 2022 Mar; 12(1):3500. PubMed ID: 35241721
[TBL] [Abstract][Full Text] [Related]
2. Long-term expression changes of immune-related genes in prostate cancer after radiotherapy.
Eke I; Aryankalayil MJ; Bylicky MA; Sandfort V; Vanpouille-Box C; Nandagopal S; Graves EE; Giaccia AJ; Coleman CN
Cancer Immunol Immunother; 2022 Apr; 71(4):839-850. PubMed ID: 34435232
[TBL] [Abstract][Full Text] [Related]
3. Long-term Tumor Adaptation after Radiotherapy: Therapeutic Implications for Targeting Integrins in Prostate Cancer.
Eke I; Makinde AY; Aryankalayil MJ; Reedy JL; Citrin DE; Chopra S; Ahmed MM; Coleman CN
Mol Cancer Res; 2018 Dec; 16(12):1855-1864. PubMed ID: 30042176
[TBL] [Abstract][Full Text] [Related]
4. Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.
Eke I; Makinde AY; Aryankalayil MJ; Sandfort V; Palayoor ST; Rath BH; Liotta L; Pierobon M; Petricoin EF; Brown MF; Stommel JM; Ahmed MM; Coleman CN
Mol Cancer Ther; 2018 Feb; 17(2):355-367. PubMed ID: 28802252
[TBL] [Abstract][Full Text] [Related]
5. Fractionated radiation therapy can induce a molecular profile for therapeutic targeting.
John-Aryankalayil M; Palayoor ST; Cerna D; Simone CB; Falduto MT; Magnuson SR; Coleman CN
Radiat Res; 2010 Oct; 174(4):446-58. PubMed ID: 20726711
[TBL] [Abstract][Full Text] [Related]
6. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells.
Aryankalayil MJ; Makinde AY; Gameiro SR; Hodge JW; Rivera-Solis PP; Palayoor ST; Ahmed MM; Coleman CN
Radiat Res; 2014 Aug; 182(2):139-48. PubMed ID: 25003313
[TBL] [Abstract][Full Text] [Related]
7. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill.
Bromfield GP; Meng A; Warde P; Bristow RG
Prostate Cancer Prostatic Dis; 2003; 6(1):73-85. PubMed ID: 12664070
[TBL] [Abstract][Full Text] [Related]
8. Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
Mohan DS; Kupelian PA; Willoughby TR
Int J Radiat Oncol Biol Phys; 2000 Feb; 46(3):575-80. PubMed ID: 10701736
[TBL] [Abstract][Full Text] [Related]
9. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
[TBL] [Abstract][Full Text] [Related]
10. 50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial.
Herrera FG; Valerio M; Berthold D; Tawadros T; Meuwly JY; Vallet V; Baumgartner P; Thierry AC; De Bari B; Jichlinski P; Kandalaft L; Coukos G; Harari A; Bourhis J
Int J Radiat Oncol Biol Phys; 2019 Feb; 103(2):320-334. PubMed ID: 30267761
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
12. The lncRNAs
Eke I; Bylicky MA; Sandfort V; Chopra S; Martello S; Graves EE; Coleman CN; Aryankalayil MJ
Mol Ther Nucleic Acids; 2021 Jun; 24():175-187. PubMed ID: 33767914
[TBL] [Abstract][Full Text] [Related]
13. Palliation of bone metastases: a survey of patterns of practice among Canadian radiation oncologists.
Chow E; Danjoux C; Wong R; Szumacher E; Franssen E; Fung K; Finkelstein J; Andersson L; Connolly R
Radiother Oncol; 2000 Sep; 56(3):305-14. PubMed ID: 10974379
[TBL] [Abstract][Full Text] [Related]
14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
15. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
16. 53BP1/RIF1 signaling promotes cell survival after multifractionated radiotherapy.
Eke I; Zong D; Aryankalayil MJ; Sandfort V; Bylicky MA; Rath BH; Graves EE; Nussenzweig A; Coleman CN
Nucleic Acids Res; 2020 Feb; 48(3):1314-1326. PubMed ID: 31822909
[TBL] [Abstract][Full Text] [Related]
17. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
Bolla M; Van Tienhoven G; Warde P; Dubois JB; Mirimanoff RO; Storme G; Bernier J; Kuten A; Sternberg C; Billiet I; Torecilla JL; Pfeffer R; Cutajar CL; Van der Kwast T; Collette L
Lancet Oncol; 2010 Nov; 11(11):1066-73. PubMed ID: 20933466
[TBL] [Abstract][Full Text] [Related]
18. Impact of elapsed treatment time on outcome of external-beam radiation therapy for localized carcinoma of the prostate.
Perez CA; Michalski J; Mansur D; Lockett MA
Cancer J; 2004; 10(6):349-56. PubMed ID: 15701266
[TBL] [Abstract][Full Text] [Related]
19. Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR).
Kim YJ; Ahn H; Kim CS; Kim YS
Radiat Oncol; 2020 Oct; 15(1):234. PubMed ID: 33032643
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
